To study the beneficial role of FSTL1, E. coli produced human FSTL1 was intravenously administrated in a murine model either before inducing ischemia or after reperfusion; to validate a therapeutic effect in a larger animal, a porcine model was subjected to 45 min of ischemia and 24 h of reperfusion and intracoronary administration of FSTL1 during the first 10 min after ischemia. Here, FSTL1 is linked to ischemia.